| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| G Ransmay. [The role of dopaminagonists in the treatment of Parkinson's disease]. Praxis. vol 94. issue 42. 2006-03-07. PMID:16277084. |
dopamine agonists have also been shown to be significantly effective in the treatment of motor oscillations and dyskinesias related to chronic levodopa treatment. |
2006-03-07 |
2023-08-12 |
human |
| William A Wolf, Gerald J Bieganski, Veronica Guillen, Laurence Migno. Enhanced 5-HT2C receptor signaling is associated with haloperidol-induced "early onset" vacuous chewing in rats: implications for antipsychotic drug therapy. Psychopharmacology. vol 182. issue 1. 2006-02-22. PMID:15986194. |
the mechanisms underlying antipsychotic-induced dyskinesias are not well understood but are widely held to be related to excessive loss of dopamine function. |
2006-02-22 |
2023-08-12 |
rat |
| Peter Hagell, M Angela Cenc. Dyskinesias and dopamine cell replacement in Parkinson's disease: a clinical perspective. Brain research bulletin. vol 68. issue 1-2. 2006-02-15. PMID:16324999. |
dyskinesias and dopamine cell replacement in parkinson's disease: a clinical perspective. |
2006-02-15 |
2023-08-12 |
human |
| Peter Hagell, M Angela Cenc. Dyskinesias and dopamine cell replacement in Parkinson's disease: a clinical perspective. Brain research bulletin. vol 68. issue 1-2. 2006-02-15. PMID:16324999. |
both increased and decreased dyskinesias have been reported from open label clinical trials of transplantation of human embryonic dopamine rich tissue in parkinson's disease patients. |
2006-02-15 |
2023-08-12 |
human |
| Paola Piccini, Nicola Pavese, Peter Hagell, Jan Reimer, Anders Björklund, Wolfgang H Oertel, Niall P Quinn, David J Brooks, Olle Lindval. Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain : a journal of neurology. vol 128. issue Pt 12. 2006-01-26. PMID:16246865. |
we obtained no evidence that dyskinesias were caused by abnormal dopamine (da) release from the grafts. |
2006-01-26 |
2023-08-12 |
Not clear |
| Jennifer L Taylor, Christopher Bishop, Paul D Walke. Dopamine D1 and D2 receptor contributions to L-DOPA-induced dyskinesia in the dopamine-depleted rat. Pharmacology, biochemistry, and behavior. vol 81. issue 4. 2005-11-28. PMID:16023708. |
dopamine d1 and d2 receptor contributions to l-dopa-induced dyskinesia in the dopamine-depleted rat. |
2005-11-28 |
2023-08-12 |
rat |
| Jennifer L Taylor, Christopher Bishop, Paul D Walke. Dopamine D1 and D2 receptor contributions to L-DOPA-induced dyskinesia in the dopamine-depleted rat. Pharmacology, biochemistry, and behavior. vol 81. issue 4. 2005-11-28. PMID:16023708. |
using a rat model of l-dopa-induced dyskinesia (lid), the contributions of dopamine d1 and d2 receptors to axial, limb, and orolingual (alo) abnormal involuntary movements (aims) elicited by l-dopa were examined. |
2005-11-28 |
2023-08-12 |
rat |
| Abraham Kovoor, Petra Seyffarth, Jana Ebert, Sami Barghshoon, Ching-Kang Chen, Sigrid Schwarz, Jeffrey D Axelrod, Benjamin N R Cheyette, Melvin I Simon, Henry A Lester, Johannes Schwar. D2 dopamine receptors colocalize regulator of G-protein signaling 9-2 (RGS9-2) via the RGS9 DEP domain, and RGS9 knock-out mice develop dyskinesias associated with dopamine pathways. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 25. issue 8. 2005-10-26. PMID:15728856. |
d2 dopamine receptors colocalize regulator of g-protein signaling 9-2 (rgs9-2) via the rgs9 dep domain, and rgs9 knock-out mice develop dyskinesias associated with dopamine pathways. |
2005-10-26 |
2023-08-12 |
mouse |
| William Bara-Jimenez, Francesco Bibbiani, Michael J Morris, Tzvetelina Dimitrova, Abdullah Sherzai, Maral M Mouradian, Thomas N Chas. Effects of serotonin 5-HT1A agonist in advanced Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. vol 20. issue 8. 2005-10-19. PMID:15791634. |
if 5-ht1a autoreceptors regulate dopamine as well as serotonin release, in parkinsonian patients inhibition of striatal serotonergic neuron firing might help maintain more physiological intrasynaptic dopamine concentrations and thus ameliorate motor fluctuations and dyskinesias. |
2005-10-19 |
2023-08-12 |
Not clear |
| Marcelo Betti Mascaro, Jackson Cioni Bittencourt, Cláudio Aparecido Casatti, Carol Fuzeti Elia. Alternative pathways for catecholamine action in oral motor control. Neuroscience letters. vol 386. issue 1. 2005-09-16. PMID:15978723. |
dopamine is of special interest since its imbalance may produce changes in basal ganglia activity, which generates abnormal movements, including jaw motor dysfunction, as in oral dyskinesia and possibly in bruxism. |
2005-09-16 |
2023-08-12 |
Not clear |
| Katherine Widnel. Pathophysiology of motor fluctuations in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. vol 20 Suppl 11. 2005-08-25. PMID:15822108. |
this body of preclinical data suggests that nonphysiological, pulsatile stimulation of dopamine receptors induces the development of motor fluctuations and dyskinesias and raises the possibility that nonpulsatile stimulation of dopamine receptors (continuous dopaminergic stimulation) might induce fewer fluctuations. |
2005-08-25 |
2023-08-12 |
Not clear |
| David J Brook. Positron emission tomography imaging of transplant function. NeuroRx : the journal of the American Society for Experimental NeuroTherapeutics. vol 1. issue 4. 2005-08-23. PMID:15717049. |
the dissociation between dopamine storage capacity, clinical improvement, and normalization of brain metabolism in pd is discussed, and possible mechanisms underlying the phenomenon of dyskinesias off medication are presented. |
2005-08-23 |
2023-08-12 |
Not clear |
| Alain Deste. [Therapeutic strategies for Parkinson's disease]. La Revue du praticien. vol 55. issue 7. 2005-08-11. PMID:15966415. |
unfortunately, after this classical "honeymoon" appear the "motor complications of dopamine therapy" (mcd), motor fluctuations and dyskinesia. |
2005-08-11 |
2023-08-12 |
Not clear |
| J M Brotchie, J Lee, K Venderov. Levodopa-induced dyskinesia in Parkinson's disease. Journal of neural transmission (Vienna, Austria : 1996). vol 112. issue 3. 2005-07-29. PMID:15614429. |
levodopa-induced dyskinesias (lid) are abnormal involuntary movements that develop progressively with repeated dopamine replacement therapy in parkinson's disease (pd). |
2005-07-29 |
2023-08-12 |
Not clear |
| C Guigoni, I Aubert, Q Li, V V Gurevich, J L Benovic, S Ferry, U Mach, H Stark, L Leriche, K Håkansson, Bernard H Bioulac, Christian E Gross, Pierre Sokoloff, Gilberto Fisone, E V Gurevich, Bertrand Bloch, Erwan Bezar. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors. Parkinsonism & related disorders. vol 11 Suppl 1. 2005-07-25. PMID:15885624. |
pathogenesis of levodopa-induced dyskinesia: focus on d1 and d3 dopamine receptors. |
2005-07-25 |
2023-08-12 |
monkey |
| C Guigoni, I Aubert, Q Li, V V Gurevich, J L Benovic, S Ferry, U Mach, H Stark, L Leriche, K Håkansson, Bernard H Bioulac, Christian E Gross, Pierre Sokoloff, Gilberto Fisone, E V Gurevich, Bertrand Bloch, Erwan Bezar. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors. Parkinsonism & related disorders. vol 11 Suppl 1. 2005-07-25. PMID:15885624. |
taking advantage of a monkey brain bank constituted to study the pathophysiology of levodopa-induced dyskinesia, we here report the changes affecting d1, d2 and d3 dopamine receptors within the striatum of four experimental groups of non-human primates: normal, parkinsonian, parkinsonian treated with levodopa without or with dyskinesia. |
2005-07-25 |
2023-08-12 |
monkey |
| M Lundblad, A Usiello, M Carta, K Håkansson, G Fisone, M A Cenc. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Experimental neurology. vol 194. issue 1. 2005-07-15. PMID:15899244. |
dopamine (da) denervated mice can exhibit behavioral and cellular signs of dyskinesia when they are treated with l-dopa, but the clinical relevance of this animal model remains to be established. |
2005-07-15 |
2023-08-12 |
mouse |
| Masahiko Tomiyama, Tamaki Kimura, Tetsuya Maeda, Kazuya Kannari, Muneo Matsunaga, Masayuki Bab. A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease. Neuroscience research. vol 52. issue 2. 2005-07-13. PMID:15893579. |
marked fluctuation of dopamine concentration in the striatum following long-term l-dopa administration contributes to the development of l-dopa-induced motor complications including l-dopa-induced dyskinesias and wearing-off in patients with parkinson's disease. |
2005-07-13 |
2023-08-12 |
rat |
| Lance A Smith, Michael J Jackson, Ghassan Al-Barghouthy, Sarah Rose, Mikko Kuoppamaki, Warren Olanow, Peter Jenne. Multiple small doses of levodopa plus entacapone produce continuous dopaminergic stimulation and reduce dyskinesia induction in MPTP-treated drug-naive primates. Movement disorders : official journal of the Movement Disorder Society. vol 20. issue 3. 2005-06-30. PMID:15490461. |
long-acting dopamine agonist drugs induce a lower incidence of dyskinesia in mptp-treated primates and patients with parkinson's disease compared to pulsatile treatment with levodopa, supporting the concept of continuous dopaminergic stimulation as a means of dyskinesia avoidance. |
2005-06-30 |
2023-08-12 |
Not clear |
| Manfred Gerlach, Maarten van den Buuse, Charles Blaha, Dirk Bremen, Peter Riedere. Entacapone increases and prolongs the central effects of l-DOPA in the 6-hydroxydopamine-lesioned rat. Naunyn-Schmiedeberg's archives of pharmacology. vol 370. issue 5. 2005-05-24. PMID:15502970. |
long-term palliative treatment of parkinson's disease (pd) with the dopamine precursor l-3,4-dihydroxyphenylalanine ( l-dopa, levodopa) is compromised by the occurrence of motor complications, most notably motor fluctuations and involuntary movements, l-dopa-induced dyskinesias. |
2005-05-24 |
2023-08-12 |
rat |